TREATMENT OF FUNCTIONAL GASTROINTESTINAL DYSPEPSIA
Main Article Content
Abstract
ABSTARCT
Prokinetic drugs (prokinetics) are drugs that enhance and coordinate muscle contractions of the gastrointestinal (GI) tract, including coordination between different intestinal segments, thereby increasing the movement of intraluminal contents. The review considers modern approaches to the use of prokinetics in the treatment of motor disorders of the gastrointestinal tract. The results of studies of various classes of drugs that have a prokinetic effect and target various pathophysiological mechanisms, including impaired antroduodenal coordination, manifested by subjective symptoms and an objective delay in gastric emptying, are presented. Currently used in clinical practice and registered in Uzbekistan, the drug domperidone still remains relevant: in the treatment of patients with functional dyspepsia, gastroparesis and gastroesophageal reflux disease, it is recommended to take it in combination with proton pump inhibitors. Domperidone has an antiemetic effect and a favorable safety profile when used for its registered indications.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Acosta A., Camilleri M. Prokinetics in gastroparesis. Gastroenterol Clin North Am. 2015;44(1):97–111. DOI: 10.1016/j.gtc.2014.11.008.
Sarosiek I., Van Natta M., Parkman H.P. et al. Effect of Domperidone Therapy on Gastroparesis Symptoms: Results of a Dynamic Cohort Study by NIDDK Gastroparesis Consortium. Clin Gastroenterol Hepatol. 2022;20(3):e452–e464. DOI: 10.1016/j.cgh.2021.05.063
Chedid V., Halawi H., Brandler J. et al. Gastric accommodation measurements by single photon emission computed tomography and two-dimensional scintigraphy in diabetic patients with upper gastrointestinal symptoms. Neurogastroenterol Motil. 2019;31(6):e13581. DOI: 10.1111/nmo.13581.
Bouras E.P., Delgado-Aros S., Camilleri M. et al. SPECT imaging of the stomach: comparison with barostat, and effects of sex, age, body mass index, and fundoplication. Single photon emission computed tomography. Gut. 2002;51(6):781–786. DOI: 10.1136/gut.51.6.781.
Carbone F., Tack J., Hoffman I. The Intragastric Pressure Measurement: A Novel Method to Assess Gastric Accommodation in Functional Dyspepsia Children. J Pediatr Gastroenterol Nutr. 2017;64(6):918–924. DOI: 10.1097/MPG.0000000000001386.
Tack J., Caenepeel P., Piessevaux H. et al. Assessment of meal induced gastric accommodation by a satiety drinking test in health and in severe functional dyspepsia. Gut. 2003;52(9):1271–1277. DOI: 10.1136/gut.52.9.1271.
Orthey P., Dadparvar S., Parkman H.P., Maurer A.H. Enhanced Gastric Emptying Scintigraphy to Assess Fundic Accommodation Using Intragastric Meal Distribution and Antral Contractility. J Nucl Med Technol. 2019;47(2):138–143. DOI: 10.2967/jnmt.118.215566
Mounsey A., Barzin A., Rietz A. Functional Dyspepsia: Evaluation and Management. Am Fam Physician. 2020;101(2):84–88. PMID: 31939638.
Cangemi D.J., Lacy B.E. Gastroparesis and functional dyspepsia: different diseases or different ends of the spectrum? Curr Opin Gastroenterol. 2020;36(6):509–517. DOI: 10.1097/MOG.0000000000000677.
Nelson A.D., Camilleri M., Acosta A. et al. Effects of ghrelin receptor agonist, relamorelin, on gastric motor functions and satiation in healthy volunteers. Neurogastroenterol Motil. 2016;28(11):1705–1713. DOI: 10.1111/nmo.12870.
Vosoughi K., Ichkhanian Y., Jacques J. et al. Role of endoscopic functional luminal imaging probe in predicting the outcome of gastric peroral endoscopic pyloromyotomy (with video). Gastrointest Endosc. 2020;91(6):1289–1299. DOI: 10.1016/j.gie.2020.01.044.
Tack J., Camilleri M., Chang L. et al. Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther. 2012;35(7):745–767. DOI: 10.1111/j.1365-2036.2012.05011.x.
Carbone F., Van den Houte K., Clevers E. et al. Prucalopride in Gastroparesis: A Randomized Placebo-Controlled Crossover Study. Am J Gastroenterol. 2019;114(8):1265–1274. DOI: 10.14309/ajg.0000000000000304
Kuo B., Barnes C.N., Nguyen D.D. et al. Velusetrag accelerates gastric emptying in subjects with gastroparesis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 study. Aliment Pharmacol Ther. 2021;53(10):1090–1097. DOI: 10.1111/apt.16344.
Chedid V., Brandler J., Arndt K. et al. Randomised Study: Effects of the 5-HT4 Receptor Agonist Felcisetrag vs Placebo on Gut Transit in Patients with Gastroparesis. Aliment. Pharmacol. Ther. 2021;53(9):1010–1020. DOI: 10.1111/apt.16304.
Chapman M.J., Jones K.L., Almansa C. et al. Blinded, Double-Dummy, Parallel-Group, Phase 2a Randomized Clinical Trial to Evaluate the Efficacy and Safety of a Highly Selective 5- Hydroxytryptamine Type 4 Receptor Agonist in Critically Ill Patients with Enteral Feeding Intolerance. JPEN J Parenter Enteral Nutr. 2021;45(1):115–124. DOI: 10.1002/jpen.1732.
Beattie D.T., Armstrong S.R., Vickery R.G. et al. The Pharmacology of TD-8954, a Potent and Selective 5-HT(4) Receptor Agonist with Gastrointestinal Prokinetic Properties. Front Pharmacol. 2011;2:25. DOI: 10.3389/fphar.2011.00025.
Beattie D.T., Higgins D.L., Ero M.P. et al. An In Vitro Investigation of the Cardiovascular Effects of the 5- HT(4) Receptor Selective Agonists, Velusetrag and TD-8954. Vascul Pharmacol. 2013;58(1–2):150–156. DOI: 10.1016/j.vph.2012.11.002.
Stakenborg N., Labeeuw E., Gomez-Pinilla P.J. et al. Preoperative administration of the 5-HT4 receptor agonist prucalopride reduces intestinal inflammation and shortens postoperative ileus via cholinergic enteric neurons. Gut. 2019;68(8):1406–1416. DOI: 10.1136/gutjnl-2018-317263
Kuo B., Scimia C., Dukes G. et al. Randomised Clinical Trial: Safety, Pharmacokinetics and Pharmacodynamics of Trazpiroben (TAK-906), a Dopamine D 2/D 3 Receptor Antagonist, in Patients with Gastroparesis. Aliment Pharmacol Ther. 2021;54(3):267–280. DOI: 10.1111/apt.16451.
Pasricha P.J., Yates K.P., Sarosiek I. et al. Aprepitant Has Mixed Effects on Nausea and Reduces Other Symptoms in Patients With Gastroparesis and Related Disorders. Gastroenterology. 2018;154(1):65–76.e11. DOI: 10.1053/j.gastro.2017.08.033.
Jacob D., Busciglio I., Burton D. et al. Effects of NK1 receptors on gastric motor functions and satiation in healthy humans: results from a controlled trial with the NK1 antagonist aprepitant. Am J Physiol Gastrointest Liver Physiol. 2017;313(5):G505–G510. DOI: 10.1152/ajpgi.00197.2017.
Carlin J.L., Lieberman V.R., Dahal A. et al. Efficacy and Safety of Tradipitant in Patients With Diabetic and Idiopathic Gastroparesis in a Randomized, Placebo-Controlled Trial. Gastroenterology. 2021;160(1):76–87.e4. DOI: 10.1053/j.gastro.2020.07.029.
Tack J., Depoortere I., Bisschops R. et al. Influence of ghrelin on interdigestive gastrointestinal motility in humans. Gut. 2006;55(3):327–333. DOI: 310.1136/gut.2004.060426.
Camilleri M., Papathanasopoulos A., Odunsi S.T. Actions and therapeutic pathways of ghrelin for gastrointestinal disorders. Nat Rev Gastroenterol Hepatol. 2009;6(6):343–352. DOI: 10.1038/nrgastro.2009.72.
Van der Ploeg L., Laken H., Sharma S. et al. Preclinical gastrointestinal prokinetic efficacy and endocrine effects of the ghrelin mimetic RM-131. Life Sci. 2014;109(1):20–29. DOI: 10.1016/j.lfs.2014.06.003.
Shin A., Camilleri M., Busciglio I. et al. Randomized controlled phase Ib study of ghrelin agonist, RM-131, in type 2 diabetic women with delayed gastric emptying: pharmacokinetics and pharmacodynamics. Diabetes Care. 2013;36(1):41–48. DOI: 10.2337/dc12-1128.
Nelson A.D., Camilleri M., Acosta A. et al. Effects of ghrelin receptor agonist, relamorelin, on gastric motor functions and satiation in healthy volunteers. Neurogastroenterol Motil. 2016;28(11):1705–1713. DOI: 10.1111/nmo.12870.
Thielemans L., Depoortere I., Perret J. et al. Desensitization of the human motilin receptor by motilides. J Pharmacol Exp Ther. 2005;313(3):1397–1405. DOI: 10.1124/jpet.104.081497.
Parkman H.P., Pagano A.P., Vozzelli M.A., Ryan J.P. Gastrokinetic effects of erythromycin: myogenic and neurogenic mechanisms of action in rabbit stomach. Am J Physiol. 1995;269(3 Pt 1):G418–G426. DOI: 10.1152/ajpgi.1995.269.3.G418.
Ray W.A., Murray K.T., Meredith S. et al. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med. 2004;351(11):1089–1096. DOI: 10.1056/NEJMoa040582.
Kusunoki H., Haruma K., Manabe N. et al. Therapeutic efficacy of acotiamide in patients with functional dyspepsia based on enhanced postprandial gastric accommodation and emptying: randomized controlled study evaluation by real-time ultrasonography. Neurogastroenterol Motil. 2012;24(6):540–545, e250–1. DOI: 10.1111/j.1365-2982.2012.01897.x.
Matsueda K., Hongo M., Tack J. et al. A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia. Gut. 2012;61(6):821–828. DOI: 10.1136/gutjnl-2011-301454.
Tack J., Janssen P., Bisschops R. et al. Influence of tegaserod on proximal gastric tone and on the perception of gastric distention in functional dyspepsia. Neurogastroenterol Motil. 2011;23(2):e32–e39. DOI: 10.1111/j.1365-2982.2010.01613.x.
Wang X.J., Burton D.D., Breen-Lyles M., Camilleri M. Gastric accommodation influences proximal gastric and total gastric emptying in concurrent measurements conducted in healthy volunteers. Am J Physiol Gastrointest Liver Physiol. 2021;320(5)G759–G767. DOI: 10.1152/ajpgi.00008.2021.
Hasler W.L., Wilson L.A. Nguyen L.A. et al. Opioid Use and Potency Are Associated With Clinical Features, Quality of Life, and Use of Resources in Patients With Gastroparesis. Clin Gastroenterol Hepatol. 2019;17(7):1285–1294.e1. DOI: 10.1016/j.cgh.2018.10.013.
Camilleri M., Sanders K.M. Opiates, the Pylorus, and Gastroparesis. Gastroenterology. 2020;159(2):414–421. DOI: 10.1053/j.gastro.2020.04.072.
Coleski R., Anderson M.A., Hasler W.L. Factors associated with symptom response to pyloric injection of botulinum toxin in a large series of gastroparesis patients. Dig Dis Sci. 2009;54(12):2634–2642. DOI: 10.1007/s10620-008-0660-9.
Arts J., Holvoet L., Caenepeel P. et al. Clinical trial: a randomized-controlled crossover study of intrapyloric injection of botulinum toxin in gastroparesis. Aliment Pharmacol Ther. 2007;26(9):1251–1258. DOI: 10.1111/j.1365-2036.2007.03467.x.
Tonini M., Cipollina L., Poluzzi E. et al. Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics. Aliment Pharmacol Ther. 2004;19(4):379–390. DOI: 10.1111/j.1365-2036.2004.01867.x.
Camilleri M., Parkman H.P., Shafi M.A. et al. Clinical guideline: management of gastroparesis. Am J Gastroenterol. 2013;108(1):18–37; quiz 38. DOI: 10.1038/ajg.2012.373.
Ishikawa T., Obara T., Akazawa M. et al. Risk of major congenital malformations associated with first-trimester exposure to propulsives: A health administrative database study in Japan. Pharmacoepidemiol Drug Saf. 2022;31(2):196–205. DOI: 10.1002/pds.5370.
Song B.G., Lee Y.C., Min Y.W. et al. Risk of domperidone induced severe ventricular arrhythmia. Sci Rep. 2020;10(1):12158. DOI: 10.1038/s41598-020-69053-4.
Sugumar A., Singh A., Pasricha P.J. A systematic review of the efficacy of domperidone for the treatment of diabetic gastroparesis. Clin Gastroenterol Hepatol. 2008;6(7):726–733. DOI: 10.1016/j.cgh.2008.02.065.
Helmers J.H. Preliminary report of domperidone (R 33182), a new antiemetic compound. A pilot study. Acta Anaesthesiol Belg. 1977;28(4):245–250. PMID: 613705.
Cowan A., Garg A.X., McArthur E. et al. Cardiovascular Safety of Metoclopramide Compared to Domperidone: A Population-Based Cohort Study. J Can Assoc Gastroenterol. 2020;4(5):e110–e119. DOI: 10.1093/jcag/gwaa041.
Chen S.L., Ji J.R., Xu P. et al. Effect of domperidone therapy on nocturnal dyspeptic symptoms of functional dyspepsia patients. World J Gastroenterol. 2010;16(5):613–617. DOI: 10.3748/wjg.v16.i5.613.
Wang F., Zhang X., Wang J. Effects of domperidone in combination with omeprazole in the treatment of chronic superficial gastritis. Pak J Med Sci. 2017;33(2):306–309. DOI: 10.12669/pjms.332.11778.
Giusti R., Mazzotta M., Filetti M. et al. Prophylactic use of antiemetics for prevention of opioid-induced nausea and vomiting: a survey about Italian physicians’ practice. Support Care Cancer. 2019;27(9):3531–3535. DOI: 10.1007/s00520-019-4663-1.
Robbins N.M., Ito H., Scheinman M.M., Goadsby P.J. Safety of domperidone in treating nausea associated with dihydroergotamine infusion and headache. Neurology. 2016;87(24):2522–2526. DOI: 10.1212/WNL.0000000000003429.
Miva H., Nagahara A., Asakawa A. et al. Evidence-based clinical practice guidelines for functional dyspepsia 2021. J Gastroenterol. 2022;57(2):47–61. DOI: 10.1007/s00535-021-01843-7.
Rettura F., Bronzini F., Campigotto M. et al. Refractory Gastroesophageal Reflux Disease: A Management Update. Front Med (Lausanne). 2021;8:765061. DOI: 10.3389/fmed.2021.765061.
Jung D.H., Huh C.W., Lee S.K et al. A Systematic Review and Meta-analysis of Randomized Control Trials: Combination Treatment With Proton Pump Inhibitor Plus Prokinetic for Gastroesophageal Reflux Disease. J Neurogastroenterol Motil. 2021;27(2):165–175. DOI: 10.5056/jnm20161.
And. R Mavlyanov, R. And. Mustafin, NH. Tukhtaeva / Characteristics of the luminal and parietal microflora of the stomach of patients with rheumatoid and reactive arthritis -Bulletin of New Medical Technologies // Volume 19, Number 2, pp. 319-322
https://scholar.google.com/scholar?oi=bibs&cluster=16572586286806347167&btnI=1&hl=ru